Regulatory PathRegulatory requirements compared

Active substance

Bacitracin

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
BACIGUENT500 UNITS/GMointment · ophthalmicPHARMACIA AND UPJOHNDiscontinued8 Sep 1948
BACITRACIN500 UNITS/GMointment · ophthalmicPADAGIS USDiscontinued9 Nov 1971
BACI-RX5,000,000 UNITS/BOTpowder · for rx compoundingX GEN PHARMSDiscontinued6 Jan 1972
BACITRACIN5,000,000 UNITS/BOTpowder · for rx compoundingAPOTHEKERNESDiscontinued21 Dec 1972
BACITRACIN500 UNITS/GMointment · ophthalmicLILLYDiscontinued
BACITRACIN500 UNITS/GMointment · ophthalmicPHARMADERMDiscontinued
BACITRACIN500 UNITS/GMointment · ophthalmicPHARMAFAIRDiscontinued
BACITRACIN5,000,000 UNITS/BOTpowder · for rx compoundingPADDOCK LLCDiscontinued
BACITRACIN10,000 UNITS/VIAL; 50,000 UNITS/VIALinjectable · injectionQUAD PHARMSDiscontinued
BACITRACIN500 UNITS/GMointment · topicalCOMBEDiscontinued
BACITRACIN500 UNITS/GMointment · topicalNASKADiscontinued

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
BACIJECT0224557150000 UNIT / VIALPOWDER FOR SOLUTION · TOPICAL; INTRAMUSCULARSTERIMAX INC
BACITIN00584908500 UNIT / GOINTMENT · TOPICALPENDOPHARM DIVISION OF PHARMASCIENCE INC
BACITRACIN OINTMENT02451026500 UNIT / GOINTMENT · TOPICALSAFETEC OF AMERICA INC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACBACITRACIN 500 UNIT/GM OINTMNT$0.05506per GM23 Sep 2026
US NADACBACITRACIN 500 UNIT/GM OINTMNT$0.07349per GM23 Sep 2026
US NADACBACITRACIN 500 UNIT/GM OINTMNT$0.11735per GM23 Sep 2026
US NADACBACITRACIN 500 UNIT/GM OINTMNT$0.0787per GM23 Sep 2026
US NADACBACITRACIN 500 UNIT/GM OINTMNT$0.09366per GM23 Sep 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Combinations containing Bacitracin

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.